I agree that this site is using cookies. You can find further informations here.
X
Raje, NS
5  results:
Search for persons X
?
1

A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN..:

Lesokhin, AM ; Arnulf, B ; Niesvizky, R...
Hematology, Transfusion and Cell Therapy.  44 (2022)  - p. S245-S246 , 2022
Link: https://doi.org/10.1016/..
 
?
2

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL ..:

Solh, M ; Bahlis, NJ ; Raje, NS...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S195-S196 , 2021
Link: https://doi.org/10.1016/..
 
?
3

B037 CAL-101: A Selective Inhibitor of PI3K p110D for the T..:

Ikeda, H ; Hideshima, T ; Fulciniti, M...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S98-S99 , 2009
Link: https://doi.org/10.1016/..
 
?
4

Denosumab, a RANK ligand inhibitor, for the management of b..:

Yee AJ ; Raje NS
https://www.dovepress.com/denosumab-a-rank-ligand-inhibitor-for-the-management-of-bone-loss-in-c-peer-reviewed-article-CIA.  , 2012
Link: https://doaj.org/article..
 
?
5

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL ..:

M Solh ; NJ Bahlis ; NS Raje...
http://www.sciencedirect.com/science/article/pii/S2531137921004788.  , 2021
Link: https://doi.org/10.1016/..
 
1-5